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Background: Sphingolipid deposition in Fabry disease causes left ventricular (LV) hypertrophy, of which the
accurate assessment is essential. Cardiovascular magnetic resonance (CMR) has been proposed as the gold
standard. However, there is debate in the literature as to whether papillary muscles and trabeculations (P&T) should
be included in LV mass (LVM).
Methods/results: We examined the accuracy of 2 CMR methods of assessing LVM and LV volumes, including
(MincP&T) or excluding (MexP&T) P&T, in a cohort of Fabry disease subjects (n = 20) compared to a matched control
group (n = 20). Significant differences between the two measurement methods were observed for LV end-diastolic
volume, LV end-systolic volume, LVM, and LV ejection fraction (LVEF) in both groups. These differences were
significantly greater in the Fabry group compared to controls, except for LVEF. P&T contributed to a greater
percentage of LVM in Fabry subjects than controls (20 ± 1% vs 13 ± 2%, p = 0.01). In the control group, both
volume-derived methods (MincP&T or MexP&T) provided accurate SV measurements compared with the internal
reference of velocity-encoded aortic flow. In the Fabry group, inclusion of P&T (MincP&T) resulted in good concordance
with phase contrast flow imaging (difference between flow and volume techniques: 1 ± 3 ml, p = 0.7).
Conclusion: The volumetric contribution of P&T in Fabry disease is markedly increased relative to healthy controls.
Failure to account for this results in significant underestimation of LVM and results in misclassification of a proportion
of subjects.
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Fabry disease is a X-linked disorder characterized by defi-
cient activity of α-galactosidase A, which leads to progres-
sive lysosomal accumulation of complex sphingolipids,
predominantly globotriaosylceramide [1]. In the myocar-
dium this typically produces a uniform pattern of left* Correspondence: gemma.figtree@sydney.edu.au
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unless otherwise stated.ventricular hypertrophy (LVH) that involves the papillary
muscles and trabeculations (P&T), as well as the ventricu-
lar walls. Cardiac death is a major contributor to mortality
in Fabry disease, and occurs most commonly secondary to
arrhythmias and heart failure. LVH and hypertension are
the factors that are most associated with cardiac death in
Fabry patients [2]. Serial monitoring of left ventricular
function (LVF) and left ventricular mass (LVM) in these
patients is therefore desirable for both monitoring the
progression of disease, and for assessing the response to
treatments such as enzyme replacement therapy (ERT).his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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posed as the ‘gold standard’ non-invasive method of meas-
uring these indices, however, there is debate in the
literature as to whether P&T should be included in the
cavity volume or the myocardial mass [3-6]. Figure 1 illus-
trates these two approaches to ventricular quantification.
The Society of Cardiovascular Magnetic Resonance task
force on standardized protocols does not currently favor
one method over the other, but suggests that inclusion
or exclusion of papillary muscles in LVM should be the
same as that used in normal reference ranges used for
comparison [7].
In this study, we compare two different CMR ap-
proaches in quantifying left ventricular volumes, function
and mass in a cohort of Fabry disease subjects compared
to controls. We hypothesized that incorporating the P&T
during measurements of LVM is of greater importance in
patients with ventricular hypertrophy.Methods
Study population
Twenty subjects with known Fabry disease (genotype
positive), from the New South Wales and Queensland
states Fabry registry databases, who had been referred
for CMR as part of clinical management were included.
To avoid any influence of gender on our analysis, only
male patients were included. Twenty age-matched male
controls were randomly selected from a database of
‘normal’ healthy volunteers with no history of cardiac
disease. The study was approved by the relevant Institu-
tional Human Ethics Committees.Figure 1 Illustrative example of ventricular assessment. The top two ro
show data from an example control subject. For each cohort, the top row
2 (MexP&T) during end-diastole (columns labelled ‘ED’) and endocardial con
views at base, middle and apex levels (‘Base’, ‘Middle’ and ‘Apex’ headings)
drawn using Method 1 (MincP&T), which includes the trabeculations and paCardiovascular magnetic resonance imaging
MRI data was acquired using Balanced Steady-State Free
Precession (bSSFP) cine imaging on a 1.5 T Tesla Signa
HDxt GE system (TE 1.5 ms; TR 3.4 ms; 20 phases; flip
angle 45°; acquisition matrix 224 × 224; FOV 35 cm; slice
thickness 8 mm; slice gap 2 mm) or a 3.0 Tesla GE system
(TE: 1.1-1.6 ms; TR: 3.1-3.6 ms; 20 phases; flip angle 40-
45°; matrix 256 × 256; in-plane resolution 1.4 mm; slice
thickness 8 mm; no inter-slice gap). Cardiac chamber vol-
umes and myocardial mass were quantified using a short
axis stack of images acquired during end-expiratory breath
hold. Phase contrast velocity encoded data was acquired
in the ascending aorta at the level of the main pulmonary
artery bifurcation using breath-held gradient echo flow-
encoded cine images acquired with 20 phases (TE: 3.8 ms;
TR: 7.0-8.3 ms; matrix 256 × 256; in-plane resolution
1.4 mm; slice thickness of 8 mm).
Image analysis
CMR images were viewed using Osirix software (http://
www.osirix-viewer.com) [8]. Analysis was performed
using the STIL analysis tool plugin for Osirix (www.stil.
net.au/downloads). LV end-diastolic and end-systolic
volumes, LV mass (LVM), LV stroke volume (SV) and
LV ejection fraction (LVEF) were obtained from the
short axis stack by manually contouring end-diastolic
and end-systolic endocardial borders and end-diastolic
epicardial borders from the base to the apex. The 4-
chamber and LVLA views were used to confirm the seg-
mentation to ensure accuracy at the base [9]. The LV
endocardial border was defined using the two methods
described below and depicted in Figure 1:ws show data from an example Fabry subject, and the bottom two
panels show epicardial and endocardial contours drawn using Method
tours during end-systole (‘ES’ columns) for representative short axis
. The bottom row for each example show the corresponding contours
pillary muscles.
Kozor et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:22 Page 3 of 7 MincP&T – Papillary muscles and trabeculations
with signal intensity within 1 standard deviation of
the myocardial signal measured in the LV free wall
were manually outlined and included in the
myocardial area. Trabeculations below 1.5 mm were
also not included in the segmentation [6].
 MexP&T-–Papillary muscles and trabeculations were
excluded from the myocardial area and included in
the blood pool by defining the endocardial border as a
continuous contour following a smooth path along
the compacted myocardium, not including the
distinct trabeculations and papillary muscles.
All endocardial and epicardial borders were contoured
manually by both an experienced CMR Radiologist
(SMG) and Cardiologist (RK). Both endocardial and epi-
cardial borders were traced at end-diastole and only the
endocardial borders at end-systole. End-diastole was de-
fined visually as the phase with the largest intracavity
volume, and end-systole as the phase with the smallest
intracavity volume. The basal slice was selected when at
least fifty percent of the left ventricular cavity was sur-
rounded by myocardium at end-diastole. The apical slice
was selected as the last frame showing intracavity blood
pool at end-diastole. LV volumes and mass were com-
pared between the 2 methods described above in both
Fabry and control subjects. As an internal reference, SV
calculated using the two methods was then compared
with aortic SV measured by velocity-encoded flow se-
quences in the ascending aorta. Many sites that employ
a MexP&T approach match the LVM calculated from
end-systole with the end-diastolic LVM (as a form of
internal reference to ensure the same volume of P&T
muscle was included in the blood pool at both end-systole
and end-disatole). We chose not to perform this step,
as this was felt unnecessary for the purposes of our
comparison. Aortic outflow was calculated off-line and
manually on a workstation (ReportCARD, GE Healthcare,
Milwaukee, WI).
To verify the reproducibility and reliability of the dif-
ferent methods, the intra-observer and inter-observer re-
peatability of LVEDV and LVESV measurements were
assessed in half of the subjects. For intra-observer vari-
ability, the measurements were performed twice by the
same observer (RK) with at least 1 week between mea-
surements. For inter-observer variability, the first mea-
surements from observer 1 were compared to the
measurements calculated by a second independent ob-
server (SG), who was blinded to the initial results.
Statistical analysis
Statistical analyses were carried out using SPSS 21 (IBM,
Armonk, NY). All continuous variables are expressed as
mean ± standard error of the mean. Categorical variablesare expressed as frequencies or percentages. Outcome
variables were compared using paired-samples t-test for
matched variables within each subject group, and
independent-samples t-test for variables between the
groups. A p-value of <0.05 was considered statistically
significant. The Bland Altman statistical test was used
to assess intra- and inter-observer variability, with the
results presented graphically including mean differences




All participants were males. The Fabry and control
groups had a mean age of 42 ± 3 vs 35 ± 1 years (p =
0.08), and range 13–66 vs 27–56 years, respectively.
Cardiovascular measures
The measures of LV volumes and mass obtained using the
two methods (MincP&T and MexP&T) are summarized in
Table 1. The two measurement methods resulted in sig-
nificantly different LV end-diastolic volume (LVEDV), LV
end-systolic volume (LVESV), LVM (measured in diastole)
and LVEF for both groups. However, the choice of method
made a more significant difference in the Fabry population.
As shown in Figure 2, the differences between MincP&T
and MexP&T methods were markedly greater in the Fabry
group compared to the controls for LVEDV, LVESV and
LVM.
By including P&T in the analysis approach (MincP&T),
the difference in LVM between Fabry subjects and con-
trols subjects was 178 ± 14 vs 130 ± 6 g (p = 0.003). This
pathological difference was less evident when P&T were
excluded (MexP&T: 144 ± 12 vs 113 ± 6 g, p = 0.03). This
proportional difference appears to be explained by the
fact that the papillary muscles and trabeculations con-
tributed to a greater percentage of cardiac mass in Fabry
patients than control subjects (20% ± 1 vs 13 ± 2%, p =
0.01; Figure 3A). Figure 3B is an illustration of the rela-
tive contribution of the papillary and trabecular volumes
to the overall mass in a Fabry patient.
In order to examine which of the two techniques was
more accurate, we compared the stroke volume derived
from ventricular contour measurements using both
methods with the stroke volume as measured by velocity-
encoded flow sequences in the ascending aorta, which is
renowned for its accuracy [10,11]. Results are shown in
Figure 4. In the control group, both volumetric methods
(MincP&T or MexP&T) gave similar values to the stroke
volume calculated from the velocity-encoded data (p = ns).
However, in the Fabry group, exclusion of P&T (MexP&T)
resulted in a significant 12% overestimation of SV com-
pared to aortic flow technique (overestimation of 11 ±
4 ml; p = 0.007). This was corrected by the inclusion of
Table 1 Comparison of differences between methods (MincP&T and MexP&T) in control and Fabry subjects
CONTROL SUBJECTS (n = 20) FABRY SUBJECTS (n = 20)
M(incP&T) M(exP&T) p-value M(incP&T) M(exP&T) p-value
LVEDV (ml) 163 ± 6 179 ± 6 <0.001 127 ± 7 160 ± 8 <0.001
LVESV (ml) 54 ± 4 71 ± 3 <0.001 34 ± 2 56 ± 3 <0.001
LVSV (ml) 108 ± 5 105 ± 5 0.2 103 ± 7 100 ± 8 0.3
LVEF (%) 67 ± 1 61 ± 1 <0.001 73 ± 1 65 ± 1 <0.001
LVM (g) 130 ± 6 113 ± 6 <0.001 178 ± 14 144 ± 12 <0.001
LVM indexed (g/m2) 66 ± 3 58 ± 3 <0.001 98 ± 8 79 ± 7 <0.001
LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, LVSV = left ventricular stroke volume, LVEF = left ventricular ejection
fraction, LVM = left ventricular mass, SV = stroke volume.
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3 ml, p = 0.7; Figure 4).
Intra- and inter-observer variability
Assessment of the intra- and inter-observer variability
showed acceptable levels of agreement for both MincP&T
and MexP&T , using LVEDV and LVESV as example cal-
culations. Figure 5 shows the Bland Altman graphs and
coefficients of repeatability.
Discussion
In this study, we demonstrate that the choice of includ-
ing or excluding papillary muscles and trabeculations in
LV mass measures can result in large differences in the
quantification of LV function and mass that is exacer-
bated in a condition classically associated with cardiac
hypertrophy. We show that in patients with Fabry dis-
ease, in which sphingolipids are deposited in myocardial
tissue, the contribution of papillary and trabecularFigure 2 Mean difference between measurement approaches
(MincP&T - MexP&T) for key left ventricular measures of function
and mass, in control and Fabry subjects. LVEDV = left ventricular
end diastolic volume, LVESV = left ventricular end systolic volume,
LVSV = left ventricular stroke volume, LVEF = left ventricular ejection
fraction, LVM = left ventricular mass.muscle to the total LV mass is markedly increased com-
pared to healthy controls. The inclusion of papillary
muscles in myocardial volume improves accuracy of
volumetric measures of LV stroke volume when com-
pared with the internal reference measure taken from
velocity encoded flow data at the aortic outflow. These
findings may have significant implications for assessment
and targeted therapy of patients with Fabry disease, as
well as other conditions associated with cardiac hyper-
trophy, and should prompt a move toward more consist-
ent standards in reporting volumetric data.
Our data demonstrate significant differences between
the two analysis approaches for both the Fabry and con-
trol groups across a range of parameters. While the im-
pact of analysis approach was modest in the control
subjects, the magnitude of these differences was much
greater in the Fabry cohort (between 10-30% - see
Figure 2). The comparison between the flow-derived
LVSV provides strong evidence that MincP&T is a more
accurate approach in the setting of Fabry-related hyper-
trophy (Figure 4), and even though for control subjects
the comparison was non-significant, it is likely that using
the MexP&T approach would introduce a bias toward
higher LVEDV, LVESV and LVSV with increasing hyper-
trophy. In a population setting, this would have the ef-
fect of over reporting in these three parameters. We also
know, from the Bland Altman plots, that MincP&T is re-
producible and reliable.
Recent data using a computer-aided contouring ap-
proach in a large sample (n = 1494) drawn from the Fra-
mingham study also supports the use of a MincP&T
approach, demonstrating that the inclusion of P&T in
the calculation of LVM results in a measureable differ-
ence in normal subjects [12]. The historic motivation for
using MexP&T contouring was primarily pragmatic – mo-
tivated by the relative speed and reproducibility of this
technique in normal subjects using manual contouring.
Early computer-based contouring routines were not cap-
able of accurate delineation of trabecular contours, hence
the use of this technique has been limited by pragmatic
Figure 3 Papillary muscles and trabecular contributions to total LVM. (A) Comparison in control versus Fabry subjects (p = 0.01). (B) Graphic
showing a mid-ventricular slice illustrating the papillary and trabecular components excluded from the LVM using the MexP&T approach (dashed
endocardial contour) compared with their inclusion via the MP&T approach (solid endocardial contour) in a Fabry subject. LVM = left ventricular mass.
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trophy, the MexP&Tapproach has difficulties in delineating
the interface between tightly packed trabeculae and com-
pacted myocardium without careful attention to detail and
close reference to the moving cine images [6]. This is
especially difficult towards the apex [12]. This technique is
therefore not suited to automation in the presence of
hypertrophy due to the increase in compacted trabecula-
tions. Although we use a manual approach in this paper,
the increasing availability of computer-aided analysis capable
of accurate MincP&T contours means that the practical
advantage of MexP&T is no longer compelling.
In the context of cardiac hypertrophy, the effect of type
of volumetric analysis approach on the estimation of car-
diac mass is of even greater importance than the func-
tional measures. In the Fabry group, papillary muscle andFigure 4 Effect of volumetric analysis method on the
determination of LVSV in control versus Fabry subjects. Aortic
stroke volume, as measured by velocity-encoded flow sequences in
the ascending aorta, was subtracted from LVSV, measured using
volumetric methods with both MincP&T or MexP&T approaches.
LVSV = left ventricular stroke volume.trabecular mass contributed to an average 20% of the total
cardiac mass, over one and a half times more than that of
the control group (Figure 3). Thus, comparing to the nor-
mal range calculated using a papillary exclusion method
(as recommended by different organisations) will not fully
account for this, and will therefore underestimate the de-
gree of hypertrophy and cardiac involvement for a patient
with Fabry disease. The distortion of this important meas-
ure may have implications for patients’ disease severity
classification and therapy management, which at our insti-
tutions is based on organ involvement and the Mainz
Severity Scale Index (MSSI) scoring system [14]. Cur-
rently, the cardiovascular score in the MSSI includes an
assessment of “cardiac muscle thickness” based on electro-
cardiogram and echocardiography features. In this study,
the inclusion of P&T in LVM measurements increased the
number of Fabry patients exceeding the upper limit of
normal from 6/20 to 11/20 after normalization by BSA
[15]. Therefore, an additional five Fabry patients were re-
classified as having an abnormally high cardiac mass using
the MincP&T approach. This effect is driven by the in-
creased contribution papillary muscle hypertrophy makes
to overall cardiac mass in Fabry disease, versus non-
deposition forms of LV hypertrophy, and has important
implications for disease severity classification and therapy
in this disease.
Only males were analysed in this study to avoid
any influence of gender on hypertrophy in general. We
acknowledge that this is a limitation considering Fabry
disease affects both genders. It is unclear whether the
results can be translated to females, given the gender
differences in Fabry cardiomyopathy regarding LVH [16].
The findings of our study have considerable import-
ance in the setting of Fabry disease due to the availability
of enzyme replacement therapy (ERT) and the targeting
of this therapy to those with identified end-organ in-
volvement. ERT has been available since 2001, and data
Figure 5 Bland Altman graphs for LVEDV and LVESV (using MincP&T) intraobserver repeatability (top panels) and interobserver
repeatability (bottom panels). The mean difference of each plot is shown as a solid line and the upper and lower limits of agreement as
dashed lines. The coefficient of repeatability for each analysis is displayed.
Kozor et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:22 Page 6 of 7over the last decade suggests that ERT has the potential
to change the prognosis of Fabry disease [17-21]. Despite
this, there remain numerous uncertainties regarding
these agents – these relate to the optimal stage for
treatment initiation, considerable heterogeneity of re-
sponse, and the magnitude of the long-term clinical
benefits. The current criteria for initiation of ERT are
variable by location, but in Australia include left ven-
tricular hypertrophy as measured by echocardiography
or cardiac MRI, or significant arrhythmia. Making use
of the MincP&T approach in this cohort may have
altered the eligibility for ERT for five of this study’s
patients. Our data strongly suggest that accurate meas-
urement of LVM is best achieved using a method
that accurately defines the endocardial border so as
to include all significant trabeculations and papillarymuscles. This analysis deliberately focused on examin-
ing subjects with Fabry disease versus controls; further
studies are required to explore if the results apply to
other types of cardiac hypertrophy.Conclusion
The volumetric contribution of papillary muscles and
trabeculations in Fabry disease is markedly increased
relative to healthy controls in males. Failure to account
for this results in significant underestimation of LVM
and results in misclassification of a proportion of sub-
jects. While Fabry patients represent an uncommon ex-
ample of hypertrophy, they underline the importance of
accurately contouring the endocardial border for quanti-
fication of left ventricular assessment.
Kozor et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:22 Page 7 of 7Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RK- conception & design, acquisition/analysis/interpretation of data,
manuscript writing; FC- manuscript writing; MC- conception, acquisition of
data, manuscript writing; CHC- interpretation of data, manuscript writing;
GF- conception & design, analysis/interpretation of data, manuscript writing;
SG- conception & design, analysis/interpretation of data, manuscript writing.
Author details
1North Shore Heart Research Group, Kolling Institute of Medical Research,
University of Sydney, Sydney, Australia. 2Department of Cardiology, Royal
North Shore Hospital, Sydney, Australia. 3Sydney Translational Imaging
Laboratory, Sydney Medical School, University of Sydney, Sydney, Australia.
4Department of Genetic Medicine, Westmead Hospital, Sydney, Australia.
5Discipline of Genetic Medicine, Sydney Medical School, University of Sydney,
Sydney, Australia. 6Heart and Lung Institute, The Prince Charles Hospital,
Brisbane, Australia. 7University of Queensland, Brisbane, Australia.
Received: 5 August 2014 Accepted: 8 January 2015
References
1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.
2. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al.
Cardiovascular events in patients with fabry disease natural history data
from the fabry registry. Journal of the American College of Cardiology.
2011;57:1093–9.
3. Weinsaft JW, Cham MD, Janik M, Min JK, Henschke CI, Yankelevitz DF, et al.
Left ventricular papillary muscles and trabeculae are significant
determinants of cardiac MRI volumetric measurements: effects on clinical
standards in patients with advanced systolic dysfunction. Int J Cardiol.
2008;126:359–65.
4. Sievers B, Kirchberg S, Bakan A, Franken U, Trappe HJ. Impact of papillary
muscles in ventricular volume and ejection fraction assessment by
cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2004;6:9–16.
5. Janik M, Cham MD, Ross MI, Wang Y, Codella N, Min JK, et al. Effects of
papillary muscles and trabeculae on left ventricular quantification: increased
impact of methodological variability in patients with left ventricular
hypertrophy. J Hypertens. 2008;26:1677–85.
6. Papavassiliu T, Kuhl HP, Schroder M, Suselbeck T, Bondarenko O, Bohm CK,
et al. Effect of endocardial trabeculae on left ventricular measurements and
measurement reproducibility at cardiovascular MR imaging. Radiology.
2005;236:57–64.
7. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized
cardiovascular magnetic resonance imaging (CMR) protocols, society for
cardiovascular magnetic resonance: board of trustees task force on
standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.
8. Rosset A, Spadola L, Ratib O, Osiri X. An open-source software for navigating
in multidimensional DICOM images. Journal of digital imaging : the official
journal of the Society for Computer Applications in Radiology. 2004;17:205–16.
9. Childs H, Ma L, Ma M, Clarke J, Cocker M, Green J, et al. Comparison of long
and short axis quantification of left ventricular volume parameters by
cardiovascular magnetic resonance, with ex-vivo validation. J Cardiovasc
Magn Reson. 2011;13:40.
10. Lotz J, Meier C, Leppert A, Galanski M. Cardiovascular flow measurement
with phase-contrast MR imaging: basic facts and implementation.
Radiographics. 2002;22:651–71.
11. Gelfand EV, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, et al.
Severity of mitral and aortic regurgitation as assessed by cardiovascular
magnetic resonance: optimizing correlation with Doppler
echocardiography. J Cardiovasc Magn Reson. 2006;8:503–7.
12. Chuang ML, Gona P, Hautvast GL, Salton CJ, Blease SJ, Yeon SB, et al.
Correlation of trabeculae and papillary muscles with clinical and cardiac
characteristics and impact on CMR measures of LV anatomy and function.
JACC Cardiovasc Imaging. 2012;5:1115–23.
13. van der Geest RJ, Buller VG, Jansen E, Lamb HJ, Baur LH, van der Wall EE,
et al. Comparison between manual and semiautomated analysis of left
ventricular volume parameters from short-axis MR images. J Comput Assist
Tomogr. 1997;21:756–65.14. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E,
et al. The Mainz Severity Score Index: a new instrument for quantifying the
Anderson-Fabry disease phenotype, and the response of patients to enzyme
replacement therapy. Clin Genet. 2004;65:299–307.
15. Maceira A, Prasad S, Khan M, Pennell D. Normalized Left Ventricular Systolic
and Diastolic Function by Steady State Free Precession Cardiovascular
Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance.
2006;8:417–26.
16. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al.
Differences in Fabry cardiomyopathy between female and male patients:
consequences for diagnostic assessment. JACC Cardiovasc Imaging.
2011;4:592–601.
17. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry
disease: a review of current management strategies. QJM : monthly journal
of the Association of Physicians. 2010;103:641–59.
18. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, et al.
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy:
evidence for a better outcome with early treatment. Circulation.
2009;119:524–9.
19. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al.
Improvement of cardiac function during enzyme replacement therapy in
patients with Fabry disease: a prospective strain rate imaging study.
Circulation. 2003;108:1299–301.
20. Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al.
Effects of enzyme-replacement therapy in patients with Anderson-Fabry
disease: a prospective long-term cardiac magnetic resonance imaging study.
Heart (British Cardiac Society). 2009;95:1103–7.
21. Da H, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of
enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry
disease: a randomised, double-blind, placebo-controlled clinical trial of
agalsidase alfa. Heart (British Cardiac Society). 2008;94:153–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
